ClinicalTrials.Veeva

Menu
M

Monash Health | Neurology Department

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Tislelizumab
Zanubrutinib
Pembrolizumab
Platinum
BGB-11417
BGB-3111
Nivolumab
ARO-APOC3
Palbociclib
Atezolizumab

Parent organization

This site is a part of Monash Health

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

80 of 138 total trials

A Feasibility Study of the Millipede Transcatheter Annuloplasty Ring System in Patients With Functional Mitral Regurgitation

To evaluate the feasibility and safety of the Millipede Transcatheter Annuloplasty Ring System in subjects with functional mitral regurgitation

Active, not recruiting
Mitral Valve Disease
Cardiovascular Diseases
Device: Millipede Transcatheter Annuloplasty Ring System (Millipede System)

This is a Phase 1/2, open-label, multicenter study designed to evaluate the safety, tolerability, and DLTs to establish the maximum tolerated dose (M...

Not yet enrolling
Locally Advanced Unresectable or Metastatic Solid Tumors
Biological: IBI354

Study consists of two parts, a part 1 dose escalation and a part 2 cohort expansion in combination with dexamethasone and carfilzomib intravenously a...

Enrolling
Relapsed/Refractory Multiple Myeloma
Drug: Carfilzomib
Drug: Dexamethasone

The three tumour streams that will be studied in this protocol are: (i) upper GI malignancies (comprising intra-hepatic/extra-hepatic cholangiocarcin...

Active, not recruiting
Malignant Female Reproductive System Neoplasm
Neuroendocrine Tumours
Drug: Ipilimumab
Drug: Nivolumab

he purpose of the study is to evaluate the efficacy, safety, and tolerability BGB-3111 plus obinutuzumab versus obinutuzumab alone in participants wi...

Active, not recruiting
Relapsed/Refractory Follicular Non-Hodgkin Lymphoma
Drug: Obinutuzumab
Drug: Zanubrutinib

This is a Phase 1b/2 study to investigate the efficacy and safety of LBL-007 plus Tislelizumab when administered in combination with bevacizumab plus...

Enrolling
Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer
Drug: 5-Fluorouracil
Drug: Tislelizumab

This is a First in Human (FIH) Phase 1, multicenter, open label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharm...

Active, not recruiting
Advanced Solid Tumors
Drug: Tislelizumab
Drug: BGB-30813

The purpose of this study is to learn whether adding abemaciclib to abiraterone plus prednisone prolongs the time before prostate cancer gets worse....

Active, not recruiting
Cytochrome P-450
Antineoplastic Agents, Hormonal
Drug: Placebo for Abemaciclib
Drug: Abemaciclib

This study is to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activity of AK112...

Enrolling
Neoplasms Malignant
Drug: AK112

This is a first-in-human (FIH), Phase 1a/1b, Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokineti...

Active, not recruiting
Advanced or Metastatic Solid Tumors
Biological: AK104
Biological: AK119

The study will determine the safety, tolerability, recommended Phase 2 dose (RP2D) and preliminary efficacy of BGB-11417 as monotherapy and in combin...

Enrolling
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasm
Drug: BGB-11417
Drug: Posaconazole

CLN-619-001 is a Phase 1, open-label, multi-center study of CLN-619 alone and in combination with pembrolizumab in patients with advanced solid tumor...

Enrolling
Advanced Solid Tumor
Drug: CLN-619
Drug: Pembrolizumab

The purpose of this study is to evaluate two study medicines (encorafenib plus cetuximab) taken alone or together with standard chemotherapy for the...

Active, not recruiting
Neoplasms
Drug: Cetuximab
Drug: Oxaliplatin

The goal of this study is to test the effectiveness, safety, and tolerability of the combination of broadly neutralizing antibodies (bNAbs) (teropavi...

Active, not recruiting
HIV Infections
Drug: Lenacapavir Tablet
Drug: Zinlirvimab
Locations recently updated

The purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with moderately to severely active ulcerative colitis...

Active, not recruiting
Ulcerative Colitis
Drug: Guselkumab
Drug: Placebo

The purpose of this study is to evaluate the efficacy, including clinical remission of guselkumab subcutaneous (SC) induction compared to placebo in...

Active, not recruiting
Colitis, Ulcerative
Drug: Guselkumab Dose 2
Other: Placebo

The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cance...

Enrolling
Breast Neoplasms
Drug: Anastrozole
Drug: Tamoxifen

This is a Phase 1/2 study of imvotamab in adult subjects with relapsed or refractory B-cell Non-Hodgkin Lymphoma. This study will consist of a dose-e...

Active, not recruiting
Marginal Zone Lymphoma
Mantle Cell Lymphoma
Drug: imvotamab

This Phase 3 study is designed to compare the efficacy and safety of mirvetuximab soravtansine vs. investigator's choice chemotherapy in patients wit...

Active, not recruiting
Epithelial Ovarian Cancer
Peritoneal Cancer
Drug: Paclitaxel
Drug: Pegylated liposomal doxorubicin

The purpose of this study is to evaluate the efficacy and safety of ociperlimab + tislelizumab compared with that of pembrolizumab in adults with PD-...

Active, not recruiting
Non-small Cell Lung Cancer
NSCLC
Drug: Placebo
Drug: Tislelizumab

Trial sponsors

BeiGene logo
W
Gilead Sciences logo
Pfizer logo
Arrowhead Pharmaceuticals logo
Boston Scientific logo
Bristol-Myers Squibb (BMS) logo
ImmunoGen logo
Mirati Therapeutics logo
M

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems